The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma
Open Access
Abstract
Multiple myeloma accounts for 1% of all new cancers worldwide. It is the second most common haematological malignancy and has a low five-year survival rate (53.2%). Myeloma remains an incurable disease and is caused by the growth of malignant plasma cells in the bone marrow. Current anti-myeloma therapies (conventional chemotherapies, immunomodulatory drugs i.e., thalidomide and its’ analogues, proteasome inhibitors, monoclonal antibodies, and radiotherapy) initially substantially debulk tumour burden, but after a period of remission ‘plateau phase’ disease invariably relapses due to tumour recrudescence from foci of minimal residual disease (MRD) and accumulating drug resistance. Therefore, there is a compelling clinical need for the development of novel treatment regimens to target MRD and effectively eliminate all remaining tumour cells. This review will discuss the potential use of oncolytic virus (OV) therapies in the treatment of myeloma. Specifically, it will focus on preclinical studies using DNA viruses (adenovirus (Ad), vaccinia virus (VV), myxoma virus (MYXV), and herpes simplex virus (HSV)), RNA viruses (reovirus (reo), coxsackie virus, measles virus (MV) and bovine viral diarrhoea virus (BVDV), and vesicular stomatitis virus (VSV)), and on four types of viruses (VV, reo, MV-NIS and VSV-IFNβ-NIS) that have been assessed clinically in a small number of myeloma patients.Keywords
This publication has 78 references indexed in Scilit:
- Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-βCancer Gene Therapy, 2012
- The genetic architecture of multiple myelomaNature Reviews Cancer, 2012
- Curative one-shot systemic virotherapy in murine myelomaLeukemia, 2012
- Thunder and Lightning: Immunotherapy and Oncolytic Viruses CollideMolecular Therapy, 2011
- Integrin αvβ5 is a primary receptor for adenovirus in CAR-negative cellsVirology Journal, 2010
- Infection and Killing of Multiple Myeloma by AdenovirusesHuman Gene Therapy, 2009
- Tumor‐associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myelomaAmerican Journal of Hematology, 2009
- Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Δ51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter geneBlood, 2007
- Measles Virus Infection of SLAM (CD150) Knockin Mice Reproduces Tropism and Immunosuppression in Human InfectionJournal of Virology, 2007
- The Hallmarks of CancerCell, 2000